Retatrutide

About Retatrutide

  • Retatrutide is a new treatment for those who are overweight or living with obesity
  • The medication has not yet received approval or become available
  • It works by targeting three different receptors at the same time
  • Clinical trials to date suggest potential weight loss of up to 24%
  • Side effects seem to be similar to those seen with other GLP-1 medications
Retatrutide: new weight loss medication in development

Retatrutide is a new medication that is currently attracting considerable attention as a potential treatment for overweight and obesity. It belongs to a new generation of drugs that are demonstrating promising results in research. Retatrutide is not yet approved or available at present. As soon as this changes, we will keep you updated.

What is Retatrutide?

  • Retatrutide is a GLP-1/GIP/GCGR agonist that is currently under development.
  • Clinical studies suggest it may aid weight loss and help regulate blood sugar levels.
  • Its mechanism of action appears to be partly similar to established agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), but retatrutide targets three receptors at once.
  • The drug remains in the research phase and has not yet been approved for use in Europe.
Mechanism of action of Retatrutide

Retatrutide targets three receptors (GLP-1, GIP, and GCGR) which play a role in appetite, metabolism, and the regulation of blood sugar. Studies indicate that this may potentially result in weight loss and improved glucose levels. As the medication is still under development, the precise effects, dosages, and long-term outcomes have yet to be determined.

Side effects of Retatrutide

In clinical trials, side effects have been reported which are similar to those seen with other GLP-1 agents, including:

  • Nausea
  • Diarrhoea
  • Fatigue

As Retatrutide is still under development, a comprehensive overview of potential side effects is not yet available. This information will be updated here as more data become available.

Research on Retatrutide

Retatrutide is currently in phase 3 of clinical development. Several large-scale studies are underway across the globe, including the so-called TRIUMPH trials conducted by manufacturer Eli Lilly. These studies are examining the effects of Retatrutide in individuals with obesity, type 2 diabetes, and other conditions. Further information is available on Eli Lilly’s official trial page.

Preliminary findings from a phase 2 study, published in the New England Journal of Medicine, indicate promising outcomes:

  • An average weight loss of up to 24% after 48 weeks of treatment.
  • Improvements in blood glucose levels and other cardiometabolic risk factors.
  • The most frequently reported side effects were mild and comparable to those seen with other GLP-1-like agents (such as nausea and diarrhoea).

These studies are ongoing. As soon as more definitive results are released, we will update this page.

Status and availability of Retatrutide
  • Retatrutide has not yet been approved in Europe.
  • At present, there is no clarity regarding its authorisation or availability.
  • As soon as this changes, we will publish the latest information here.
What can you do now?
  • Keep following this page for the latest updates on Retatrutide.
  • Explore alternative weight loss treatments that are available: Wegovy.
Sources

Affiliated doctors

You know perfectly well what's good and what isn't good for you. Nevertheless, making the right choice can be difficult. We are Doctoronline. We believe in self-management when it comes to your health.